C3.ai(US:AI) Prnewswireยท2025-10-02 01:15Group 1 - The core allegation against C3.ai, Inc. is that the company misled investors regarding the impact of its CEO's health on business prospects, specifically in closing deals and executing growth strategies [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to CEO health problems and management reorganization [2] - Following the announcement, C3.ai's stock price dropped from $22.13 per share to $16.47 per share, marking a decline of over 25% [2] Group 2 - A class action has been filed on behalf of individuals and entities that purchased C3.ai securities between February 26, 2025, and August 8, 2025, with a deadline for lead plaintiff submissions set for October 21, 2025 [1][3] - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [4]